Two major pharmaceutical companies, GlaxoSmithKline and Purdue Pharma, are considering Apple's ResearchKit for drug R&D
Big Pharma Eyes iPhone For Drug R&D — Pharmaceutical giants like GlaxoSmithKline and Purdue Pharma are considering Apple's ResearchKit platform for gathering medical research data.
Context & Ripple Effects
Apple launched ResearchKit in March 2015 as an open framework for medical researchers to build iPhone-based studies, and coverage at the time emphasized how it minimizes obstacles to patient participation. Within four months, BuzzFeed reports that two major drugmakers — GlaxoSmithKline and Purdue Pharma — are weighing the platform for drug R&D, a shift from academic pilots to commercial pharmaceutical pipelines.
The interest lands alongside reporting that Apple is working with US researchers on DNA testing through ResearchKit, signaling the platform's ambitions beyond symptom-tracking apps. The consideration phase proved durable: by mid-2016 GlaxoSmithKline would run a rheumatoid arthritis study on ResearchKit, becoming the first drugmaker to use the framework for clinical research.
First-order effects
- GlaxoSmithKline and Purdue Pharma gain a potential recruitment and data-collection channel that reaches patients through iPhones already in their pockets, bypassing clinic-based enrollment.
- Apple moves ResearchKit's customer base from academic medical centers toward pharmaceutical companies, whose budgets and trial volumes dwarf university studies.
Second-order effects
- Rival drugmakers face pressure to match iPhone-based trials once a competitor like GSK demonstrates lower recruitment friction, making device platforms a competitive variable in clinical development.
- Consumer hardware makers adjacent to health data — not just Apple — become potential vendors to pharma, shifting supplier relationships from lab equipment toward smartphone ecosystems.
Third-order effects
- If drugmakers institutionalize ResearchKit-style studies, clinical-trial infrastructure consolidates around consumer device platforms, with Apple positioned as gatekeeper over both participant reach and the data standards pharma must adopt.
The trend: Pharmaceutical R&D is migrating patient recruitment and data collection onto consumer smartphone platforms, with Apple's ResearchKit setting the de facto standard.